Patent · US Active

Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines)

US9944708B2 · kind B2 · utility

0Cited by

3References

5Claims

0Family size

Assignee

BioNTech AG · DE

Inventors

Klaus Pfizenmaier · Tiefenbronn, DE
Harald Wajant · Echterdingen, DE
Dieter Moosmayer · Berlin, DE
Thomas Wuest · Bellinzona, CH

Key dates

Filing date	Nov 25, 2014
Grant date	Apr 17, 2018
Priority date	—
Expiry date	Mar 3, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.